{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:45:35Z","timestamp":1789202735591,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ek0109472"],"award-info":[{"award-number":["JP20ek0109472"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.braindev.2026.104520","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:46:38Z","timestamp":1772772398000},"page":"104520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5\u00a0years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report"],"prefix":"10.1016","volume":"48","author":[{"given":"Yukimune","family":"Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kawaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritomo","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Katata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Uneoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakaba","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Yokomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Haginoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2026.104520_bb0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr Clin N Am"},{"key":"10.1016\/j.braindev.2026.104520_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.braindev.2026.104520_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.braindev.2026.104520_bb0020","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/jcm12082839","article-title":"Effectiveness of Nusinersen in type 1, 2 and 3 spinal muscular atrophy: Croatian real-world data","volume":"12","author":"Belancic","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.braindev.2026.104520_bb0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2026.104520_bb0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene Abeparvovec: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.braindev.2026.104520_bb0035","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to Nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.braindev.2026.104520_bb0040","article-title":"Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.braindev.2026.104520_bb0045","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.braindev.2026.104520_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.braindev.2026.104520_bb0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.braindev.2026.104520_bb0060","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2026.104520_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2026.104520_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-03597-4","article-title":"Analysis of SMN protein in umbilical cord blood and postnatal peripheral blood of neonates with SMA: a rationale for prompt treatment initiation to prevent SMA development","volume":"20","author":"Otsuki","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2026.104520_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-025-04276-4","article-title":"Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series","volume":"25","author":"Svoboda","year":"2025","journal-title":"BMC Neurol"},{"key":"10.1016\/j.braindev.2026.104520_bb0080","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2026.104520_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2025.104410","article-title":"Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment","volume":"47","author":"Kato","year":"2025","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2026.104520_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1230889","article-title":"Case report: a case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment","volume":"14","author":"Nigro","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.braindev.2026.104520_bb0095","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213799","article-title":"Gestational age at birth and clinical manifestations of spinal muscular atrophy","volume":"105","author":"Farrar","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2026.104520_bb0100","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification","volume":"10","author":"Proud","year":"2023","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:17:59Z","timestamp":1774034279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760426000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0387760426000215"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104520","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5\u00a0years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104520"}}